Comparable efficacy of bictegravir/emtricitabine/tenofovir alafenamide and doravirine/lamivudine/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemia. [PDF]
Calza L +6 more
europepmc +1 more source
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model. [PDF]
Collins LB, Le A, Nicol MR.
europepmc +1 more source
Combined tenofovir, lamivudine, and dolutegravir treatment increases leptin and FABP4 expression in human subcutaneous adipose tissue. [PDF]
Zanardo LW +8 more
europepmc +1 more source
The Epidemiology of HIV-1 Resistance to Two-Drug Regimens in Multicenter Cohort From Poland-A Cross-Sectional Study. [PDF]
Załęski A +7 more
europepmc +1 more source
Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials. [PDF]
Post FA +10 more
europepmc +1 more source
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. [PDF]
Curteis T +17 more
europepmc +1 more source
Lamivudine resistance in untreated chronic hepatitis B patients in Turkey
Semra TUNÇBİLEK +3 more
doaj
Long-Term Effectiveness and Tolerability of Dolutegravir/Lamivudine in Korea: A 3-Year Follow Up Study. [PDF]
Seong JE +10 more
europepmc +1 more source
HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]
Tchiakpe E +4 more
europepmc +1 more source
A systematic review and meta-analysis of hepatitis B virus drug resistance and escape mutations in low- and middle-income countries. [PDF]
Asamoah EME +4 more
europepmc +1 more source

